Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and DMARD use in the general population, explore racial disparities and describe approaches to begin to address these challenges.
You Might Also Like
Also By This Author
Watch this space for our full report.